NCT07169825View on ClinicalTrials.gov

Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA in Patients With Compromised Renal and/or Bone Marrow Function

NANot yet recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 13, 2026

Primary Completion Date

September 1, 2026

Study Completion Date

September 1, 2028

Conditions
Lu-177 PSMA
Interventions
DRUG

Lu-177

Given by IV

OTHER

SPECT

SPECT/CT

Trial Locations (1)

77030

MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

GE Healthcare
All Listed Sponsors
collaborator

GE Healthcare

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER